Janssen affiliate and Dutch company ink $1.6B deal to develop cancer drug

Dec 03, 2018

Cilag, an affiliate of Janssen, is teaming up with a Netherlands-based biopharma company called Argenx to develop a treatment for certain cancers. 

The drug, Cusatuzumab, is already being tested on patients with acute myeloid leukemia. Under the deal, the companies will work on developing the treatment for a range of blood cancers and other hematological illnesses. 

Argenx specializes in antibody-based therapies for autoimmune diseases and cancer. Under the deal, Janssen will pay Argenx $300 million in cash and Johnson & Johnson Innovation will invest $200 million in the company. Argenx will be able to co-promote Cusatuzumab in the U.S. and then split the worldwide sales with Cilag. Pending certain milestones, the deal could be worth up to $1.6 billion. 

Read the full Reuters report.

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments